Normal tension glaucoma is a form of glaucoma in which the optic nerve sustains progressive damage and vision is gradually lost, even though eye pressure stays within the range doctors consider statistically normal. In most types of glaucoma, elevated intraocular pressure (IOP) is the main culprit, but in NTG the pressure readings typically fall below 21 mmHg, the traditional cutoff for “high.” This makes NTG harder to catch, harder to explain, and in some ways harder to treat. A mix of vascular insufficiency, structural vulnerability at the optic nerve head, genetics, and systemic health conditions all appear to contribute, and treatment still centers on lowering eye pressure further, though researchers are actively exploring strategies that go beyond pressure alone.
Why Eye Pressure Alone Does Not Explain the Damage
In a healthy eye, the optic nerve head sits at a boundary where the pressure inside the eye pushes from one side and the pressure of the cerebrospinal fluid (CSF) surrounding the brain and optic nerve pushes from the other. The difference between these two pressures across the thin plate of tissue called the lamina cribrosa matters more than either pressure in isolation. Patients with NTG tend to have lower CSF pressure, which means the pressure difference across the lamina cribrosa can be just as steep as it is in someone with frankly elevated eye pressure.1PubMed Central. Cerebrospinal fluid pressure and glaucoma One study measured this translaminar pressure gradient directly and found a significant negative correlation between the gradient and the amount of surviving nerve tissue at the optic disc in NTG patients, meaning a steeper gradient corresponded to more damage.2PubMed Central. The Difference in Translaminar Pressure Gradient and Neuroretinal Rim Area in Glaucoma and Healthy Subjects
Blood supply to the optic nerve head is the other major piece. Research has consistently linked NTG to impaired vascular autoregulation, the mechanism that normally keeps blood flow to the eye steady even when blood pressure fluctuates. When autoregulation fails, the optic nerve becomes vulnerable to dips in blood pressure that a healthy eye would ride out without trouble.3PubMed Central. Ocular Blood Flow and Normal Tension Glaucoma This vascular fragility helps explain why so many systemic conditions linked to poor circulation show up alongside NTG.
Systemic Conditions That Travel With NTG
NTG is not just an eye disease in the way that high-pressure glaucoma sometimes is. A large case-control study found that several systemic conditions were significantly more common in people with NTG than in matched controls. Systemic hypotension stood out the most, roughly quadrupling the odds. Diabetes, peripheral vascular disease, and Raynaud syndrome each roughly doubled or tripled the odds. Migraine roughly doubled the odds, and anemia showed a similar pattern.4PubMed Central. Multiple Systemic Vascular Risk Factors Are Associated With Low-Tension Glaucoma Chronic low vascular perfusion, Raynaud phenomenon, migraine, and nocturnal drops in blood pressure have all been cited as primary contributors.5PubMed Central. Update on Normal Tension Glaucoma
Migraine deserves special attention. It is an independent risk factor for visual field loss in NTG, separate from gender, with an adjusted risk ratio of about 2.6 for progression. Disc hemorrhage, another marker of worsening, carried a similar risk ratio in the same analysis.6PubMed. Risk factors for progression of visual field abnormalities in normal-tension glaucoma The connection between migraine and NTG is thought to reflect a shared tendency toward vascular spasm and impaired blood-flow regulation, a concept sometimes called primary vascular dysregulation.
Aggressively treated high blood pressure is another risk that surprises many patients. Antihypertensive medications that drop blood pressure too low at night can starve the optic nerve of adequate perfusion during sleep, a time when ocular blood flow is already reduced. So paradoxically, one of the risk factors for NTG is over-treatment of systemic hypertension, not the hypertension itself.5PubMed Central. Update on Normal Tension Glaucoma
The Nocturnal Blood Pressure Problem
Everyone’s blood pressure drops somewhat during sleep, but the degree of that drop varies. People whose nighttime blood pressure falls by more than about 20 percent from daytime levels are called “over-dippers,” and this pattern is linked to faster central visual field loss in NTG. One study followed NTG patients for an average of nearly five years and found that over-dippers lost central visual field sensitivity at roughly double the rate of normal dippers. About 60 percent of over-dippers experienced fast central field progression, compared with roughly 20 to 24 percent of those with moderate or minimal nighttime dips.7PubMed. Fast Central Visual Field Progression in Patients With Normal-Tension Glaucoma and Nocturnal Blood Pressure Dip
A population-based study in the Maracaibo Aging Study reinforced the point: low nighttime blood pressure alone was not significantly associated with glaucoma damage, but extreme dipping was. This suggests it is the sudden, steep drop rather than a chronically low blood pressure that does the harm, probably by creating a window during which perfusion to the optic nerve falls below the threshold the tissue can tolerate.8PubMed Central. Glaucomatous Optic Neuropathy Associated with Nocturnal Dip in Blood Pressure: Findings from the Maracaibo Aging Study Some clinicians now ask NTG patients to undergo 24-hour ambulatory blood pressure monitoring, and if extreme dipping is found, they may adjust the timing of blood pressure medications so the biggest dose is taken in the morning rather than at bedtime.
Genetic Contributions
Most NTG cases do not trace to a single gene, but a small fraction do. About two percent of NTG cases are driven primarily by mutations in one of three genes: optineurin (OPTN), TANK-binding kinase 1 (TBK1), or myocilin (MYOC).9PubMed. Familial normal tension glaucoma genetics TBK1 duplication, meaning an extra copy of the gene rather than a point mutation, has been confirmed in mouse models to produce features closely resembling human NTG, with optic nerve damage occurring at normal eye pressure. The excess TBK1 protein appears to be directly toxic.10PubMed Central. Transgenic TBK1 mice have features of normal tension glaucoma
Two percent may sound trivial, but genetic testing matters in families with multiple members affected by NTG at younger ages. OPTN mutations, for example, are associated with a particularly aggressive disease course, and identifying them early can change how closely relatives are monitored. Research into these genes has also opened potential therapeutic pathways, since the mutant proteins converge on processes like autophagy and neuroinflammation that could eventually be targeted with drugs.11PubMed Central. Molecular genetics of inherited normal tension glaucoma
Oxidative Stress and Immune Activation
Beyond vascular and structural causes, cellular-level damage plays a role in NTG. Oxidative stress, essentially an imbalance between harmful reactive oxygen molecules and the cell’s ability to neutralize them, damages retinal ganglion cells through pathways that impair mitochondrial function and trigger inflammation.12PubMed Central. Regulatory mechanisms of retinal ganglion cell death in normal tension glaucoma and potential therapies The same oxidative stress can provoke immune cells in the retina and optic nerve head to present antigens, essentially setting off an immune response against the eye’s own nerve tissue.13Investigative Ophthalmology & Visual Science. Mechanisms of Immune System Activation in Glaucoma: Oxidative Stress-Stimulated Antigen Presentation by the Retina and Optic Nerve Head Glia This autoimmune-like component is one reason researchers are interested in neuroprotective treatments that do not simply lower eye pressure but instead protect nerve cells from damage at its source.
How NTG Is Diagnosed
Because pressure is normal by standard measurements, NTG is often caught late or by accident during a routine dilated eye exam. The classic signs on examination include cupping of the optic disc, thinning of the nerve fiber layer, and characteristic visual field defects that progress over time. Disc hemorrhages, small flame-shaped bleeds at the edge of the optic disc, are especially common in NTG and carry clinical significance. They tend to appear at the lower-temporal rim and are associated with faster visual field loss, particularly within the central ten degrees of vision.14PubMed. Characteristics of visual field progression in patients with normal-tension glaucoma with optic disk hemorrhages
Corneal properties also enter the diagnostic picture. People with NTG tend to have thinner corneas and lower corneal hysteresis, a measure of how the cornea absorbs and dissipates energy. One study found NTG eyes had a mean corneal hysteresis of about 9.0 mmHg, lower than eyes with high-pressure glaucoma or ocular hypertension.15PubMed. Ocular response analyser to assess hysteresis and corneal resistance factor in low tension, open angle glaucoma and ocular hypertension Low corneal hysteresis may mean that standard pressure measurements slightly underestimate the true stress on the optic nerve, and it appears to be an independent predictor of glaucoma diagnosis beyond what corneal thickness alone tells you.16Eye. Combining corneal hysteresis with central corneal thickness and intraocular pressure for glaucoma risk assessment
When NTG Is Not Really NTG
One of the trickiest aspects of diagnosis is ruling out conditions that mimic NTG. Tumors pressing on the visual pathway, particularly pituitary adenomas and meningiomas, can cause optic nerve damage and visual field loss that look like glaucoma. In a study of 126 patients diagnosed with NTG who had at least one atypical feature, brain imaging revealed clinically relevant pathology in about 14 percent. The most common findings were pituitary adenomas and meningiomas along the optic nerve or skull base.17PubMed Central. Results of Neuroimaging in Patients with Atypical Normal-Tension Glaucoma
Neuroimaging is not needed for every NTG patient, but certain red flags warrant it: visual field loss that does not match the pattern of optic disc damage, loss that respects the vertical midline (suggesting a brain lesion rather than an eye problem), rapid progression, prominent pallor of the optic disc rather than the typical cupping, or diagnosis in someone under fifty. These flags overlap with features of compressive optic neuropathy, and catching a tumor early can be life-changing.
Treatment Still Starts With Lowering Pressure
Even though eye pressure is already in the normal range, lowering it further is the only treatment approach with strong trial evidence behind it. The landmark Collaborative Normal Tension Glaucoma Study demonstrated that achieving a 30 percent or greater reduction in IOP slowed the rate of visual field loss.18PubMed. Collaborative normal tension glaucoma study A separate analysis that accounted for the confounding effect of cataracts (which develop more often after glaucoma surgery and can themselves worsen visual field test results) found that untreated eyes had roughly a 60 percent survival rate at three years and 40 percent at five years, compared with about 80 percent at both time points for treated eyes.19PubMed. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma
These numbers are meaningful, but they also reveal the limits of pressure-lowering alone. Even with treatment, some patients continue to lose vision, which underscores the role of non-pressure factors in the disease.
Medications and the Question of Neuroprotection
First-line drops for NTG are typically prostaglandin analogs, which lower IOP by increasing fluid drainage from the eye. But one medication has attracted particular interest for reasons beyond pressure. In a clinical trial comparing brimonidine (an alpha-2 agonist) to timolol (a beta-blocker), both drugs lowered pressure to a similar degree, yet only about 9 percent of the brimonidine group showed visual field progression over the study period, compared with roughly 39 percent in the timolol group.20PubMed Central. Clinical Evidence for Neuroprotection in Glaucoma Because the pressure reduction was equivalent, the difference in outcomes has been interpreted as possible evidence that brimonidine has a neuroprotective effect independent of its pressure-lowering action. The evidence is intriguing but not yet definitive enough to change standard guidelines, partly because the trial had significant dropout rates.
Laser and Surgical Options
Selective laser trabeculoplasty (SLT) has gained traction as a treatment for NTG, either as a first-line option or as an add-on when drops are not enough. In one study of 41 eyes, SLT produced about a 15 percent reduction in IOP at twelve months and cut the number of daily eye drops patients needed by roughly a quarter.21PubMed Central. Efficacy of selective laser trabeculoplasty for normal tension glaucoma: 1 year results A larger multicenter study confirmed significant IOP reductions at one year in both first-line and second-line SLT groups, with the first-line group achieving a mean drop of about 17 percent. Pretreatment IOP that was already quite low and prior use of medication before SLT were associated with a higher chance of treatment failure.22BMJ Open. Efficacy and safety of first-line or second-line selective laser trabeculoplasty for normal-tension glaucoma: a multicentre cohort study
Microinvasive glaucoma surgery (MIGS) devices are increasingly combined with cataract surgery in NTG patients. In a study of 45 NTG patients who underwent MIGS with cataract extraction, mean IOP fell modestly from about 13.7 to 12.3 mmHg at two and a half years, and the average number of daily medications dropped from two to about one. When success was defined as reaching a target pressure with fewer medications, roughly two-thirds of patients met that definition at a year and a half. Patients who received two different MIGS devices targeting different drainage pathways had better results than those who received only one.23PubMed Central. Safety and efficacy of microinvasive glaucoma surgery with cataract extraction in patients with normal-tension glaucoma A meta-analysis of MIGS complications found that the most common issues were device malposition and minor bleeding in the front of the eye, each occurring in roughly 10 to 20 percent of cases depending on the device type, though most complications were transient.24PubMed Central. Efficacy analysis of microinvasive glaucoma surgery alone or in combination with phacoemulsification in patients with normal tension glaucoma: a systematic review and meta-analysis
Newer Imaging and Early Detection
One of the more promising advances in NTG care is the use of optical coherence tomography angiography (OCT-A), which maps tiny blood vessels in the optic nerve head without needing a dye injection. In a cohort of glaucoma suspects who had not yet developed clear NTG, researchers looked for “microvasculature dropout,” defined as localized loss of the smallest blood vessels visible on OCT-A. About half of the suspects who eventually converted to NTG had microvasculature dropout at baseline, compared with only about 6 percent of those who did not convert. Both the presence of dropout and lower vessel density in the deep layers of the optic disc predicted who would go on to develop NTG.25PubMed. Microvasculature Dropout and Development of Normal Tension Glaucoma in Glaucoma Suspects: The Normal Tension Glaucoma Suspect Cohort Study
This kind of vascular imaging could eventually shift NTG management from reactive to predictive. If you can identify someone at high risk before nerve damage becomes visible on standard tests, you can start treatment years earlier and potentially preserve much more vision.
Population Differences
NTG is notably more common in East Asian populations than in populations of European descent. Japanese, Korean, and Chinese epidemiological studies consistently report that NTG accounts for a larger share of all open-angle glaucoma cases in those countries. A comparison of Korean and Western NTG patients found structural differences: Korean patients tended to have thinner corneas and different optic disc measurements than their Western counterparts, even after accounting for disease severity.26PubMed. Comparison of clinical characteristics between Korean and Western normal-tension glaucoma patients These differences matter because diagnostic cutoffs and risk calculators developed in one population may not translate cleanly to another.
Living With NTG and Quality of Life
NTG affects daily life in ways that overlap substantially with high-pressure glaucoma but are not identical. A study comparing vision-related quality of life between NTG and standard open-angle glaucoma patients found that NTG patients tended to score slightly better across most categories, including near and far activities, driving, and mental health, though the differences were mostly not large enough to be statistically significant. Social functioning and feelings of dependency were the two areas where high-pressure glaucoma patients fared significantly worse.27Journal of Glaucoma. Comparison of Vision-related Quality of Life Between Normal Tension Glaucoma and Primary Open-angle Glaucoma
What the quality-of-life data do not capture is the particular anxiety that comes with having a disease whose mechanism is not fully understood. Many patients with NTG describe frustration at being told their pressure is “normal” while their vision is declining. The psychological burden of uncertainty, especially for younger patients diagnosed before age fifty, deserves more clinical attention than it currently receives. Ongoing monitoring through regular visual field tests and optic nerve imaging remains essential, because the disease can be stable for years and then accelerate, particularly if systemic health changes or nocturnal blood pressure patterns shift.